Home › New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo
 

Keywords :   


New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo

2014-06-14 19:01:06| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: English read more

Tags: to with type shows

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
28.04Weekly Recap: U.K. Government Announces Plastic Wipes Ban; Unicharm Starts Selling Recycled Diaper
28.04'Buying a first home is harder when you're single'
27.04CDC Blames \'Vampire Facials\' for HIV Infections
More »